Clearside Biomedical (CLSD) Getting Somewhat Positive Media Coverage, Accern Reports

News stories about Clearside Biomedical (NASDAQ:CLSD) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clearside Biomedical earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3663761280547 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

CLSD stock opened at $11.75 on Friday. The stock has a market capitalization of $374.02, a PE ratio of -5.06 and a beta of -5.48. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.57 and a current ratio of 2.90. Clearside Biomedical has a 1-year low of $5.30 and a 1-year high of $15.06.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Wednesday, March 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.05. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.10 million. Clearside Biomedical had a negative return on equity of 131.22% and a negative net margin of 17,094.20%. equities analysts forecast that Clearside Biomedical will post -2.27 earnings per share for the current year.

Several analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Clearside Biomedical in a research note on Tuesday. BidaskClub raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Zacks Investment Research downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. ValuEngine cut Clearside Biomedical from a “sell” rating to a “strong sell” rating in a report on Monday, February 5th. Finally, JMP Securities reiterated an “outperform” rating and set a $25.00 target price on shares of Clearside Biomedical in a report on Monday, March 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $19.83.

In other news, Director Gerald D. Cagle bought 7,500 shares of the stock in a transaction on Thursday, March 22nd. The stock was purchased at an average price of $11.89 per share, for a total transaction of $89,175.00. Following the acquisition, the director now owns 23,441 shares in the company, valued at $278,713.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 20.90% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Clearside Biomedical (CLSD) Getting Somewhat Positive Media Coverage, Accern Reports” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3295951/clearside-biomedical-clsd-getting-somewhat-positive-media-coverage-accern-reports.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

EPAM Systems  Raised to Buy at Zacks Investment Research
EPAM Systems Raised to Buy at Zacks Investment Research
VirnetX   Shares Down 6.3%
VirnetX Shares Down 6.3%
Cleveland-Cliffs   Shares Down 6%
Cleveland-Cliffs Shares Down 6%
Brokerages Expect Badger Meter  to Announce $0.40 EPS
Brokerages Expect Badger Meter to Announce $0.40 EPS
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Citrix Systems  Stock Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Citrix Systems Stock Price
Scripps Networks Interactive  Receives Daily News Impact Score of 0.12
Scripps Networks Interactive Receives Daily News Impact Score of 0.12


© 2006-2018 Ticker Report. Google+.